Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine reduces cigarette smoking.

M E Jarvik1, N H Caskey, W C Wirshing

  • 1University of California Los Angeles School of Medicine 90073, USA. mjarvik@ucla.edn

Addiction (Abingdon, England)
|November 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural mechanisms of mindfulness: reduced neural reactivity to social-evaluative threat accounts for mindfulness intervention effects on inflammatory gene expression.

Brain, behavior, and immunity·2026
Same author

Social support and fear-inhibition: an examination of underlying neural mechanisms.

Social cognitive and affective neuroscience·2024
Same author

Getting in touch: A neural model of comforting touch.

Neuroscience and biobehavioral reviews·2021
Same author

Preexisting mild sleep disturbance as a vulnerability factor for inflammation-induced depressed mood: a human experimental study.

Translational psychiatry·2016
Same author

Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.

Schizophrenia research·2001
Same author

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.

Archives of general psychiatry·2001
Same journal

Longitudinal association of switching to dual cigarette and e-cigarette use vs. continued exclusive cigarette smoking with tobacco-specific nitrosamine and nicotine intake.

Addiction (Abingdon, England)·2026
Same journal

Novel product, familiar challenges: Navigating uncertainty in oral nicotine pouch regulation.

Addiction (Abingdon, England)·2026
Same journal

Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trial.

Addiction (Abingdon, England)·2026
Same journal

Alcohol consumption and the risks of morbidity and mortality across 39 diseases and conditions: A population-based cohort study in Korea.

Addiction (Abingdon, England)·2026
Same journal

A cross-sectional and prospective examination of alcohol use and misuse among adult twin and sibling pairs discordant for neighborhood socio-economic disadvantage.

Addiction (Abingdon, England)·2026
Same journal

The Cannabis Research Image Database (CRESIDA): A standardized and validated image set for studying cannabis cue reactivity.

Addiction (Abingdon, England)·2026
See all related articles

Bromocriptine significantly reduced smoking behavior in heavy smokers, decreasing cigarette consumption and nicotine levels. This suggests dopamine plays a key role in reinforcing smoking habits.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • Nicotine, found in cigarettes, triggers dopamine release, a neurotransmitter linked to drug reinforcement.
  • Dopaminergic pathways are implicated in the reinforcing effects of addictive substances.

Purpose of the Study:

  • To investigate the effect of bromocriptine, a dopamine agonist, on smoking behavior in humans.
  • To test the hypothesis that bromocriptine can decrease smoking by modulating dopaminergic activity.

Main Methods:

  • A double-blind, randomized, placebo-controlled study involving 20 heavy smokers.
  • Participants received placebo or one of two doses of bromocriptine (2.50 mg, 3.75 mg) over three sessions.
  • Smoking behavior, plasma nicotine and cotinine levels, and withdrawal symptoms were recorded.

Related Experiment Videos

Main Results:

  • Increasing bromocriptine dosage led to significant reductions in total puffing time, number of cigarettes smoked, and puff frequency.
  • Plasma nicotine and cotinine levels decreased significantly with higher bromocriptine doses.
  • Subjective measures showed decreased cigarette craving, and improved scores on the Profile of Mood States (POMS) Vigor and Depression subscales.

Conclusions:

  • The findings support the hypothesis that dopaminergic mechanisms are central to cigarette smoking reinforcement.
  • Bromocriptine demonstrates potential as a therapeutic agent for smoking cessation by targeting dopamine pathways.